Completing data — refresh the page later to see the latest
268535-76-8DescriptionCetus has introduced a stable rDNA interleukin-2 (rIL-2) for the treatment of renal cell carcinoma. Recent studies showed that rIL-2 in combination with lymphokine activated killer cells or tumor infiltrating lymphocytes induced regression or partial regression in patients with advanced metastatic cancers.
DefinitionA type of biological response modifier (a substance that can improve the body’s natural response to disease). It stimulates the growth of certain disease-fighting blood cells in the immune system. Also called IL-2.